Treatment of immunoglobulin A nephropathy with targeted-release budesonide (Kinpeygo ®▾ )
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
This article explores the evolving treatment of IgA nephropathy, highlighting targeted-release budesonide as the first licensed therapy to reduce proteinuria and slow disease progression when combined with optimised supportive care. This article was sponsored by Stada UK. Stada UK had no involvement in the creation of the content, which was independently developed by the authors Richard Hull, Ayat Faggad and Lisa Willcocks in partnership with MA Healthcare. Stada UK reviewed the article for technical accuracy and compliance only. Prescribing information and adverse event reporting can be found at the end of this article. UK-KINPE-215 | February 2026
Fields of Study & Subjects
Renal Diseases and Glomerulopathies
Chronic Kidney Disease and Diabetes
Renal Transplantation Outcomes and Treatments
Publication details
- Journal / source
- Journal of Kidney Care
- Volume
- 11
- Issue
- 2
- Pages
- 60–66
- Publication date
- 2 March 2026
- Language
- EN